Clinical Trials · NCT02003209
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- National Cancer Institute (NCI)
- Enrollment
- 315
- Start date
- Feb 2014
- Locations
- 732 sites, United States, Puerto Rico
- Primary endpoint
- Percent of Patients With Pathological Complete Response (pCR) in the Breast and Post Therapy Lymph Nodes